Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 4, 2009

View Archived Issues

Roche scientists claim Aurora kinase inhibitors and their use in cancer therapy

AstraZeneca and Astex scientists jointly impart novel BACE inhibitors

AstraZeneca scientists present new GABA-A2 receptor agonists with antipsychotic activity

Otsuka discloses novel prodrugs of tolvaptan

Recent sanofi-aventis patent reports new adenosine A3 receptor antagonists

Algeta to enroll U.S. patients into phase III trial of Alpharadin in HRPC in 2010

Compugen announces discovery of ovarian cancer biomarker CGEN-327

Hollis-Eden implements cost-cutting plan to focus on advancing Triolex and Apoptone

PTC completes enrollment in pivotal PTC-124 muscular dystrophy trial

Laminin-111 a potential therapy for alpha7 integrin congenital myopathy

Corcept reports results from clinical study of Corlux and Risperdal in weight gain

Novel antibiotic derived from the metazoan Hydra: Hydramacin-1

Foamix and VIB sign codevelopment agreement to investigate Caspase-14 for psoriasis

GlaxoSmithKline develops quinoline NK3 receptor antagonists with enhanced CNS activity

Sangamo BioSciences initiates phase I CCR5-ZFP trial in HIV/AIDS

InterMune reports results from phase III CAPACITY studies of pirfenidone

Rigel presents update on clinical development and partnership discussions for R-788

FDA approveds Zealand's IND for phase I ZP-1848 trial

Achaogen initiates phase I ACHN-490 trial in healthy volunteers

Pieris validates efficacy of Anticalin product candidate PRS-050 in several preclinical models

Results from phase II 6R-BH4 study in peripheral arterial disease not significant

Senesco announces results from efficacy, toxicology and dose-ranging studies of SNS-01

Daiichi Sankyo and Kissei to launch Urief tablets for Dysuria in Japan

FDA grants priority review for Cinryze for HAE